Product Code: 02-PARPIS-26
From £299.00
Deadline to order: 28/02/2026
BRCA1, BRCA2 and HRR testing for Ovarian and Prostate cancer in the context of PARP inhibitor prescription (FFPE). This EQA is sponsored.
The scope of this EQA involves, testing for variants in the BRCA1, BRCA2 and other HRR genes in ovarian and prostate cancers in the context of PARP inhibitors therapy.NOT suitable for labs testing for recurrent variants only.
CNV, NGS, Panel testing
English, French, German, Italian, Spanish
FFPE
Yes
September 2026
September - November 2026
May - June 2027
You can complete purchase on our secure partner site.
The scheme is designed to assess the entire diagnostic pipeline of a laboratory, including sample receipt and processing, analytical processing (genotyping), and reporting (biological and clinical interpretation of the test result) in the context of a clinical referral, as well as reporting clarity, content and clerical accuracy.
Three mock clinical cases with matching samples. Samples provided are real human tumour tissue paraffin embedded (FFPE) and/or artificial FFPE (designed to simulate real patient samples). One 10um FFPE section per case is provided.
Samples are provided as cut sections (rolled scrolls / curls) only – we cannot provide slide mounted materials.
Participants will receive an individual report including educational advice and a scheme report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics allowing participants to benchmark their results.
Each laboratory will also receive a single certificate listing all EQAs participated in with performance result for each year.
Participants are expected to test samples according to their routine strategy, to return a clinical report with interpretation in the context of targeted PARP inhibitor treatment for the tumour type, and to complete the data collection form.
This EQA is supported by an educational grant from AstraZeneca and MSD, fees are subsidised so there is a reduced cost for participants. The EQA providers acknowledge and thank AstraZeneca and MSD for this support.
The number of participants is limited, please register early to make sure you don’t miss out.
Open to laboratories from ALL countries (note: some restrictions may apply due to sanctions, delivery network exceptions, restrictions on importation etc). This EQA is provided in collaboration with GenQA.
added wishlist!
View Wishlist
View Wishlist
Express your interest in ''.
